Smith & Nephew SNATS, Inc. (NYSE:SNN) Shares Sold by Schechter Investment Advisors LLC

Schechter Investment Advisors LLC decreased its holdings in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 8.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 32,196 shares of the medical equipment provider’s stock after selling 3,119 shares during the quarter. Schechter Investment Advisors LLC’s holdings in Smith & Nephew SNATS were worth $913,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. J. Goldman & Co LP acquired a new stake in Smith & Nephew SNATS during the fourth quarter worth $47,700,000. Envestnet Asset Management Inc. grew its stake in shares of Smith & Nephew SNATS by 15.6% in the first quarter. Envestnet Asset Management Inc. now owns 618,691 shares of the medical equipment provider’s stock valued at $17,552,000 after buying an additional 83,341 shares in the last quarter. Northern Trust Corp grew its stake in shares of Smith & Nephew SNATS by 169.9% in the fourth quarter. Northern Trust Corp now owns 508,392 shares of the medical equipment provider’s stock valued at $12,496,000 after buying an additional 320,054 shares in the last quarter. Causeway Capital Management LLC acquired a new stake in shares of Smith & Nephew SNATS in the fourth quarter valued at $11,820,000. Finally, New York State Common Retirement Fund grew its stake in shares of Smith & Nephew SNATS by 19.5% in the first quarter. New York State Common Retirement Fund now owns 291,148 shares of the medical equipment provider’s stock valued at $8,260,000 after buying an additional 47,567 shares in the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew SNATS Price Performance

SNN stock opened at $30.06 on Tuesday. Smith & Nephew SNATS, Inc. has a 1 year low of $23.69 and a 1 year high of $31.72. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.33 and a current ratio of 2.89. The stock’s 50 day moving average price is $29.37 and its 200 day moving average price is $27.54. The firm has a market cap of $13.16 billion, a P/E ratio of 13.91, a PEG ratio of 0.93 and a beta of 0.69.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on SNN shares. HSBC downgraded Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Friday, April 25th. Hsbc Global Res downgraded Smith & Nephew SNATS from a “strong-buy” rating to a “hold” rating in a report on Friday, April 25th. Finally, Canaccord Genuity Group boosted their target price on Smith & Nephew SNATS from $27.00 to $28.00 and gave the company a “hold” rating in a report on Thursday, May 1st. Six investment analysts have rated the stock with a hold rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $28.00.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.